{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:11:32Z","timestamp":1789150292775,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijgc.2025.102863","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T08:16:47Z","timestamp":1772266607000},"page":"102863","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune checkpoint inhibitors in clear cell ovarian carcinoma and mixed gynecologic clear cell cohorts: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0889-7425","authenticated-orcid":false,"given":"Mariana Macambira","family":"Noronha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Felipe Costa","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3819-7550","authenticated-orcid":false,"given":"Lara de Holanda Juca","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valbert Oliveira Costa","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9240-6840","authenticated-orcid":false,"given":"Zoe","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Aparecida Schiefler","family":"Gazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Caroline Fonseca","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3980-034X","authenticated-orcid":false,"given":"Ana Carolina","family":"Veneziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.ijgc.2025.102863_bib1","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian cancer: a review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102863_bib2","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12885-021-08061-7","article-title":"Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study","volume":"21","author":"Zhu","year":"2021","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.ijgc.2025.102863_bib3","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41571-023-00819-1","article-title":"Heterogeneity and treatment landscape of ovarian carcinoma","volume":"20","author":"Veneziani","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"10177","key":"10.1016\/j.ijgc.2025.102863_bib4","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"issue":"7378","key":"10.1016\/j.ijgc.2025.102863_bib5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.ijgc.2025.102863_bib6","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102863_bib7","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.ijgc.2025.102863_bib8","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.3390\/cancers15123220","article-title":"Chasing immune checkpoint inhibitors in ovarian cancer: novel combinations and biomarker discovery","volume":"15","author":"Colombo","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102863_bib9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ygyno.2018.09.001","article-title":"Genomics to immunotherapy of ovarian clear cell carcinoma: unique opportunities for management","volume":"151","author":"Oda","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102863_bib10","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102863_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/jamaoncol.2024.6797","article-title":"Pembrolizumab in patients with advanced clear cell gynecological cancer: A Phase 2 nonrandomized clinical trial","volume":"11","author":"Kristeleit","year":"2025","journal-title":"JAMA Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.102863_bib12","article-title":"Stage 1 results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas (NCT03355976)","volume":"40","author":"Dizon","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.102863_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102991","article-title":"Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial","volume":"79","author":"Gupta","year":"2025","journal-title":"EClinicalmedicine"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102863_bib14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13048-021-00862-5","article-title":"Efficacy of PD-1\/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis","volume":"14","author":"Zhu","year":"2021","journal-title":"J Ovarian Res"},{"issue":"20","key":"10.1016\/j.ijgc.2025.102863_bib15","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1080\/14796694.2025.2530378","article-title":"Efficacy of PD-1\/PDL-1 inhibitors for ovarian cancer: a systematic review and network meta-analysis","volume":"21","author":"Ahmadi","year":"2025","journal-title":"Future Oncol"},{"key":"10.1016\/j.ijgc.2025.102863_bib16","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102863_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ijgc.2025.102863_bib18","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ijgc.2025.102863_bib19","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.ijgc.2025.102863_bib20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"suppl 8","key":"10.1016\/j.ijgc.2025.102863_bib21","doi-asserted-by":"crossref","first-page":"CT162","DOI":"10.1158\/1538-7445.AM2023-CT162","article-title":"Abstract CT162: a phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the clear cell ovarian, endometrial, cervical cancer cohorts","volume":"83","author":"Chae","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijgc.2025.102863_bib22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ygyno.2025.10.040","article-title":"Immune checkpoint inhibitors for recurrent ovarian clear cell carcinoma: real-world outcomes from a Korean multicenter study","volume":"203","author":"Chung","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.102863_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2022-ESGO.397","article-title":"RA-324-ESGO Phase 2 results from the LIO-1 STUDY (NCT04042116; ENGOT-GYN3\/AGO\/LIO): efficacy and safety of lucitanib + nivolumab in patients with advanced gynaecological malignancies","volume":"32","author":"Concin","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102863_bib24","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaoncol.2025.1916","article-title":"Nivolumab and ipilimumab combination treatment in advanced ovarian and endometrial clear cell cancers: A nonrandomized clinical trial","volume":"11","author":"Gao","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijgc.2025.102863_bib25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2024.03.027","article-title":"Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: an NRG oncology study GY016","volume":"186","author":"Gien","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"suppl 15","key":"10.1016\/j.ijgc.2025.102863_bib26","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.1200\/JCO.2020.38.15_suppl.6091","article-title":"Combination immunotherapy with ipilimumab and nivolumab in patients with rare gynaecological malignancies","volume":"38","author":"Klein","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.102863_bib27","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1200\/JCO.2025.43.16_suppl.5515","article-title":"A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512)","volume":"43","author":"Lee","year":"2025","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ijgc.2025.102863_bib28","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1158\/1078-0432.CCR-25-0201","article-title":"Durvalumab versus Physician\u2019s Choice Chemotherapy in Recurrent Ovarian Clear Cell adenocarcinoma (MOCCA\/APGOT-OV2\/GCGS-OV3): a Multicenter, Randomized, Phase 2 Trial","volume":"31","author":"Ngoi","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102863_bib29","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S1470-2045(24)00437-6","article-title":"Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Peng","year":"2024","journal-title":"Lancet Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.102863_bib30","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1200\/JCO.2022.40.16_suppl.5572","article-title":"Potential clinical activity of pembrolizumab monotherapy in ovarian sex cords, rare epithelial carcinoma, and other rare ovarian tumor histotypes: the French AcS\u00e9 pembrolizumab study from Unicancer","volume":"40","author":"Ray-Coquard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.102863_bib31","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1200\/JCO.2025.43.16_suppl.5573","article-title":"EON: Phase II trial of etigilimab (MPH313) in combination with nivolumab in patients with recurrent platinum-resistant clear cell ovarian cancer","volume":"43","author":"Son","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5-6","key":"10.1016\/j.ijgc.2025.102863_bib32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000358730","article-title":"Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter Italian trials in ovarian cancer (MITO-9)","volume":"86","author":"Esposito","year":"2014","journal-title":"Oncology"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102863_bib33","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","article-title":"PD-L1:CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways","volume":"51","author":"Zhao","year":"2019","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102863_bib34","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102863_bib35","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10456-020-09734-w","article-title":"Are antiangiogenics a good \u2018partner\u2019 for immunotherapy in ovarian cancer?","volume":"23","author":"Garc\u00eda-Mart\u00ednez","year":"2020","journal-title":"Angiogenesis"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102863_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010069","article-title":"Genetic and therapeutic heterogeneity shape the baseline and longitudinal immune ecosystem of ovarian clear cell carcinoma","volume":"12","author":"Xia","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102863_bib37","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ygyno.2021.07.005","article-title":"ARID1A mutation\/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer","volume":"162","author":"Kuroda","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102863_bib38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/PAS.0000000000001975","article-title":"Loss of major histocompatibility complex Class I, CD8 + tumor-infiltrating lymphocytes, and PD-L1 expression in ovarian clear cell carcinoma","volume":"47","author":"Lin","year":"2023","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102863_bib39","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1038\/s41598-025-89270-z","article-title":"Infiltration of CD8+ cytotoxic T-cells and expression of PD-1 and PD-L1 in ovarian clear cell carcinoma","volume":"15","author":"Fu","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijgc.2025.102863_bib40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ygyno.2024.01.032","article-title":"The emerging and challenging role of PD-L1 in patients with gynecological cancers: an updating review with clinico-pathological considerations","volume":"184","author":"Santoro","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102863_bib41","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.34165","article-title":"The prevalence of mismatch repair deficiency in ovarian cancer: a systematic review and meta-analysis","volume":"151","author":"Atwal","year":"2022","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102863_bib42","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/PGP.0000000000000682","article-title":"Diffuse intratumoral stromal inflammation in ovarian clear cell carcinoma is associated with loss of mismatch repair protein and high PD-L1 expression","volume":"40","author":"Lin","year":"2021","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102863_bib43","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygyno.2018.02.009","article-title":"Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer","volume":"149","author":"Xiao","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"14","key":"10.1016\/j.ijgc.2025.102863_bib44","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1158\/1078-0432.CCR-23-0824","article-title":"Of context, quality, and complexity: fine-combing tumor mutational burden in immunotherapy-treated cancers","volume":"31","author":"Niknafs","year":"2025","journal-title":"Clin Cancer Res."},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.102863_bib45","first-page":"TPS2671","article-title":"ARC101-P1-101: A first-in-human phase 1 study of ARC101, a next generation T cell engager (TCE), in patients with advanced solid tumors","volume":"43","author":"Bhave","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.102863_bib46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ygyno.2025.05.016","article-title":"Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma","volume":"198","author":"Iida","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102863_bib47","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1186\/s12885-024-13125-5","article-title":"Molecular profiling reveals novel therapeutic targets and clonal evolution in ovarian clear cell carcinoma","volume":"24","author":"Chao","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijgc.2025.102863_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102977","article-title":"Clearer Horizons: the latest advances in clear cell ovarian cancer treatment","volume":"138","author":"Blanc-Durand","year":"2025","journal-title":"Cancer Treat Rev"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:33:32Z","timestamp":1780306412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25019875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1048891X25019875"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102863","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors in clear cell ovarian carcinoma and mixed gynecologic clear cell cohorts: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102863","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102863"}}